Lack of pharmacokinetic interaction between cholestyramine and acipimox, a new lipid lowering drug.
作者信息
de Paolis C, Farina R, Pianezzola E, Valzelli G, Celotti F, Pontiroli A E
出版信息
Br J Clin Pharmacol. 1986 Oct;22(4):496-7. doi: 10.1111/j.1365-2125.1986.tb02926.x.
Abstract
摘要
相似文献
1
Lack of pharmacokinetic interaction between cholestyramine and acipimox, a new lipid lowering drug.考来烯胺与一种新型降脂药物阿昔莫司之间不存在药代动力学相互作用。
Br J Clin Pharmacol. 1986 Oct;22(4):496-7. doi: 10.1111/j.1365-2125.1986.tb02926.x.
2
Clinical pharmacokinetics of hypolipidaemic drugs.降血脂药物的临床药代动力学
Clin Pharmacokinet. 1978 Nov-Dec;3(6):425-39. doi: 10.2165/00003088-197803060-00001.
3
Bioavailability and pharmacokinetics in man of acipimox, a new antilipolytic and hypolipemic agent.新抗脂解及降血脂药物阿西莫司在人体中的生物利用度和药代动力学
J Int Med Res. 1981;9(5):381-6. doi: 10.1177/030006058100900515.
4
Acipimox in combination with low dose cholestyramine for the treatment of type II hyperlipidaemia.阿西莫司联合小剂量考来烯胺治疗II型高脂血症。
Br J Clin Pharmacol. 1990 Jul;30(1):49-54. doi: 10.1111/j.1365-2125.1990.tb03742.x.
5
Interaction of naproxen with cholestyramine.萘普生与消胆胺的相互作用。
Biopharm Drug Dispos. 1984 Jan-Mar;5(1):33-42. doi: 10.1002/bdd.2510050106.
6
Lack of a physicochemical interaction between metronidazole and cholestyramine.甲硝唑与消胆胺之间缺乏物理化学相互作用。
Int J Antimicrob Agents. 2007 Oct;30(4):372-4. doi: 10.1016/j.ijantimicag.2007.06.006. Epub 2007 Jul 31.
7
Lack of acipimox-digoxin interaction in patient volunteers.患者志愿者中阿西莫司与地高辛无相互作用。
Hum Exp Toxicol. 1992 Sep;11(5):357-9. doi: 10.1177/096032719201100509.
8
Effectiveness of cholestyramine in the detoxification of zearalenone as determined in mice.在小鼠体内测定的考来烯胺对玉米赤霉烯酮的解毒效果。
Bull Environ Contam Toxicol. 1995 Jan;54(1):128-34. doi: 10.1007/BF00196279.
9
Metabolism of apolipoprotein B in primary moderate hypercholesterolaemia: effects of acipimox and cholestyramine therapy.原发性中度高胆固醇血症中载脂蛋白B的代谢：阿西莫司和考来烯胺治疗的效果
Eur J Med Res. 1995 Oct 16;1(1):38-48.
10
Aggressive lipid-lowering therapy beneficial after bypass grafting, say researchers.研究人员称，积极的降脂治疗在冠状动脉搭桥术后有益。
Am J Health Syst Pharm. 1997 Mar 15;54(6):626. doi: 10.1093/ajhp/54.6.626a.
引用本文的文献
1
Acipimox in combination with low dose cholestyramine for the treatment of type II hyperlipidaemia.阿西莫司联合小剂量考来烯胺治疗II型高脂血症。
Br J Clin Pharmacol. 1990 Jul;30(1):49-54. doi: 10.1111/j.1365-2125.1990.tb03742.x.
本文引用的文献
1
Lack of pharmacokinetic interaction of colestipol and fenofibrate in volunteers.考来替泊与非诺贝特在志愿者体内不存在药代动力学相互作用。
Eur J Clin Pharmacol. 1980 Jun;17(6):459-63. doi: 10.1007/BF00570164.
2
Reduced triglyceridemia and increased high density lipoprotein cholesterol levels after treatment with acipimox, a new inhibitor of lipolysis.
Atherosclerosis. 1981 Feb-Mar;38(3-4):267-71. doi: 10.1016/0021-9150(81)90042-3.
3
Bioavailability and pharmacokinetics in man of acipimox, a new antilipolytic and hypolipemic agent.新抗脂解及降血脂药物阿西莫司在人体中的生物利用度和药代动力学
J Int Med Res. 1981;9(5):381-6. doi: 10.1177/030006058100900515.
4
Radioimmunoassay of acipimox in human plasma and urine.人血浆和尿液中阿西莫司的放射免疫分析
Pharmacol Res Commun. 1984 Nov;16(11):1081-90. doi: 10.1016/s0031-6989(84)80072-7.
5
Colestipol plus nicotinic acid in treatment of heterozygous familial hypercholesterolaemia.考来替泊加烟酸治疗杂合子家族性高胆固醇血症。
Lancet. 1981 Feb 7;1(8215):296-8. doi: 10.1016/s0140-6736(81)91910-3.
6
The interaction between cholestyramine and drugs.消胆胺与药物之间的相互作用。
Proc Soc Exp Biol Med. 1965 Oct;120(1):60-5. doi: 10.3181/00379727-120-30443.
7
Effects of acipimox, a nicotinic acid derivative, on lipolysis in human adipose tissue and on cholesterol synthesis in human jejunal mucosa.
Clin Sci (Lond). 1985 Jan;68(1):83-8. doi: 10.1042/cs0680083.
8
The effect of colestipol hydrochloride on the bioavailability and pharmacokinetics of clofibrate.盐酸考来烯胺对氯贝丁酯生物利用度和药代动力学的影响。
J Clin Pharmacol. 1979 Nov-Dec;19(11-12):721-5. doi: 10.1002/j.1552-4604.1979.tb01642.x.
Zotero 插件